Physician profile
Patrick Coady
NPI 1760736755
$4,083.39
in general payments reported to CMS, 2019-2025
19 companies · $954 in 2025
The $954 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $948 · 2020: $171 · 2021: $174 · 2022: $233 · 2023: $1,064 · 2024: $541 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $778.43 | 2022-2025 | Durysta, Ozurdex, Lumigan |
| Regeneron Healthcare Solutions, INC. | $710.72 | 2019-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $395.74 | 2022-2025 | Envista Mx60 Iol, Ic-8 Apthera Iol, Stellaris |
| Alcon Vision LLC | $353.27 | 2019 | |
| Astellas Pharma US INC | $303.22 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $280.38 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $250.75 | 2019-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $192.10 | 2019-2020 | |
| Sight Sciences, INC. | $128.47 | 2020 | |
| Neurotech Pharmaceuticals, INC. | $126.27 | 2025 | |
| Mallinckrodt Hospital Products INC. | $107.58 | 2021 | |
| Sun Pharmaceutical Industries INC. | $99.20 | 2023-2025 | Cequa |
| Apellis Pharmaceuticals, INC. | $92.67 | 2023-2025 | Syfovre |
| Eyepoint US, INC. | $74.64 | 2023 | |
| Allergan, INC. | $58.33 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $57.55 | 2019 | |
| Ani Pharmaceuticals, INC. | $37.96 | 2025 | Yutiq, Iluvien |
| Oyster Point Pharma, INC. | $23.17 | 2025 | Tyrvaya |
| Horizon Therapeutics Plc | $12.94 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Coady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.